Health Care

Explore Novo Nordisk’s new low‑dose Wegovy trial, NNC0721‑8060 launch, and recent renal setbacks—see how these moves reshape the obesity market and investor outlook.

Johnson & Johnson’s Q3 earnings signal a strong dividend, solid finances and an innovative pipeline—why analysts stay “strong buy” ahead of Oct 20, 2026.

Danaher’s modest stock rise reflects strong earnings, strategic acquisitions and FDA‑cleared diagnostics, amid a healthcare sector buoyed by breakthrough drug and vaccine data.

Coloplast Q3 earnings reveal steady growth, higher margins and strong R&D focus amid rising rates, positioning the medical‑device firm for future value‑based success.

How Bristol‑Myers Squibb’s pipeline, strategic partnerships and regulatory focus shape its growth—insights on oncology, immune‑mediated diseases and smarter acquisitions.

Gilead Sciences executive share trades: Form 4 & Form 144 filings show routine purchases and sales, confirming regulatory compliance while the biotech pipeline advances toward future approvals.

Incite Corp boosts its cell‑therapy pipeline with a long‑term partnership that secures advanced equipment, scales production, and accelerates clinical readiness.

GSK’s tax refund, director share buy, and new compliance board seat boost liquidity, governance, and readiness for value‑based pharma markets.

UK equity market reacts to July RPI data, highlights Smith & Nebhew CFO exit, CMA probe on Trainline, and growth from Oxford Nanopore and discoverIE.

Takeda’s new strategy blends AI‑driven drug discovery, lean corporate restructuring, proactive regulatory dialogue, and disciplined finance to boost innovation, speed and shareholder value.